Literature DB >> 6423614

Ceftazidime and renal function.

K Alestig, B Trollfors, R Andersson, L Olaison, M Suurküla, S R Norrby.   

Abstract

Glomerular filtration rate (GFR) as measured by 51Chrome-EDTA clearance, decreased with a mean of 10 ml/min during therapy with ceftazidime 2 g bid in 16 patients with initial GFR of 30 to 110 ml/min. A significant increase in the excretion of urinary alanine aminopeptidase was also found. In another three patients with initial GFR of 17-22 ml/min increases in serum creatinine during therapy were noted. These observations indicate that ceftazidime should be used with caution in patients with impaired renal function and not be combined with nephrotoxic drugs until the safety of such combinations has been studied.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6423614     DOI: 10.1093/jac/13.2.177

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  14 in total

1.  Urinary alanine-aminopeptidase (AAP) excretion in patients with urinary tract infection treated with ceftazidime (CAZ) or cefotaxime (CTX) plus tobramycin (TOB).

Authors:  A Wiecek; F Kokot; W Grzeszczak
Journal:  Int Urol Nephrol       Date:  1988       Impact factor: 2.370

2.  Lesson of the month 2: An easily missed cause of confusion.

Authors:  Ben Oliveira; Sangita Chaterjee; Aine Burns
Journal:  Clin Med (Lond)       Date:  2016-10       Impact factor: 2.659

3.  Pharmacokinetics and tissue concentrations of ceftazidime in burn patients.

Authors:  R A Walstad; L Aanderud; E Thurmann-Nielsen
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 4.  Side effects of cephalosporins.

Authors:  S R Norrby
Journal:  Drugs       Date:  1987       Impact factor: 9.546

5.  Population pharmacokinetics of continuous infusion ceftazidime.

Authors:  B C Frame; B F Facca; D P Nicolau; S N Triesenberg
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447

Review 6.  Adverse reactions and interactions with newer cephalosporin and cephamycin antibiotics.

Authors:  S R Norrby
Journal:  Med Toxicol       Date:  1986 Jan-Feb

7.  Dosage adjustment for ceftazidime in patients with impaired renal function.

Authors:  R van Dalen; T B Vree; A M Baars; E Termond
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Renal tolerance of imipenem/cilastatin and other beta-lactam antibiotics in rats.

Authors:  K Sack; J Herhahn; R Marre; E Schulz
Journal:  Infection       Date:  1985       Impact factor: 3.553

9.  Correlation of the pharmacokinetic parameters of amikacin and ceftazidime.

Authors:  Duangchit Panomvana; Sam-Ang Kiatjaroensin; Danabhand Phiboonbanakit
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

10.  Influence of age on the pharmacokinetics of ceftazidime in acutely ill, adult patients.

Authors:  B Ljungberg; I Nilsson-Ehle
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.